ARTICLE | Clinical News
Myrbetriq mirabegron regulatory update
March 18, 2013 7:00 AM UTC
Astellas' Astellas Pharma Canada Inc. subsidiary said Health Canada approved Myrbetriq mirabegron to treat overactive bladder (OAB) with symptoms of urgency, urgency incontinence and urinary frequency...